Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novartis Ireland Limited .
Filed returns
23
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Novartis Ireland Limited | Health | Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) | 27 | On lobbying.ie |
| May–Aug 2026 | Novartis Ireland Limited | Health | Life Science Strategy (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | IIEA event on EU Presidency and Public Health (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Novartis Ireland Limited | Health | Supporting a Health Policy Partnership Initiative for them to run a roundtable and draft a white paper with policy stakeholders. (Public policy or programme) | 26 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Forwarding letter to Dept of Health about access to innovative treatment for Irish patients (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | World Urticaria Day event (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | Advocate for Life Science Strategy (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Launch of the Rare Disease National Strategy at Department of Health (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Letter to Tanaiste about access to innovative treatment for Irish patients (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | IIEA event with a panel of speakers about Developing a National Life Sciences Vision for Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Implementation of SMA onto the Heel prick test (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2025 | Novartis Ireland Limited | Health | Rare diseases conference, as an official event of the Irish EU Presidency (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Timely inclusion of SMA in heal prick test (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2024 | Novartis Ireland Limited | Health | Implementation of SMA testing into the heel prick test for newborns (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 25 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Health | Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) | 6 | On lobbying.ie |
| Jan–Apr 2024 | Novartis Ireland Limited | Environment | EU Mercury Committee to approve a process which is a more efficient use of scarce raw materials (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2022 | Novartis Ireland Limited | Health | Update of SmartD8 Heart of Our City Social Prescribing Project. Discussion on national Illness/wellness festival with Healthy Ireland support. Partnerships/collaborations to support the Healthcare system. (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Novartis Ireland Limited | Health | Expansion of Newborn Screening (Legislation) | 2 | On lobbying.ie |
| May–Aug 2017 | Novartis Ireland Limited | Health | Highlight delay in reimbursing Entresto (Heart Failure medine), the first new innovation in heart failure in a decade considered cost effective in July 2016 (Matters involving public funds) | 23 | On lobbying.ie |
| May–Aug 2016 | Novartis Ireland Limited | Health | Ensure that the 2016 Framework Agreement on the Pricing and Supply of Medicines is resolved by aggreement, not legislation (Public policy or programme) | 5 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 22 | 95.7% | |
| Environment | 1 | 4.3% |